Look­ing to re­tain its run­ner-up po­si­tion in HIV, Mer­ck scores two new ap­provals for HIV ther­a­pies

Mer­ck $MRK scored two new drug OKs in HIV, of­fer­ing a pair of an­ti­retro­vi­ral ther­a­pies to pa­tients. But they’re un­like­ly to of­fer much of a chal­lenge to ei­ther the mar­ket leader, Gilead, or its heavy­weight ri­vals at Vi­iV.

Mer­ck’s Del­stri­go will soon hit the mar­ket with its com­bo of do­ravirine, lamivu­dine and teno­fovir diso­prox­il fu­marate. That drug, though, al­so comes with a boxed warn­ing re­gard­ing post-treat­ment acute ex­ac­er­ba­tion of he­pati­tis B in­fec­tions. Pifel­tro, mean­while, is a non-nu­cle­o­side re­verse tran­scrip­tase in­hibitor which will be pre­scribed as part of oth­er com­bi­na­tion ther­a­pies avail­able to the HIV com­mu­ni­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER